WASHINGTON — FDA Commissioner Martin Makary offered more details into the agency’s recently announced plans to place ...

An infant named KJ has made history as the first patient to be treated with an in vivo CRISPR gene editing therapy designed ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

The Garden State is looking to grow into the next big biotech hub. | The Garden State is looking to grow into the next big ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA ...

In its yearly survey of international clinicians and patients, Philips illustrated significant gaps in people’s trust when it ...

Julius Clinical is intertwining its roots with that of Peachtree BioResearch Solutions. | Netherlands-based Julius Clinical ...

RA Ventures, also known as Raven, is a healthcare accelerator for the prominent life sciences venture capital firm. The ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate ...